# Treatment of Major Depression

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/treatment-of-major-depression/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the molecular mechanisms and treatment strategies for depression, with a particular emphasis on antidepressant medications, ketamine, NMDA receptor antagonists, and neurobiological pathways. It covers topics such as treatment-resistant depression, glutamate signaling, cognitive impairment, and synaptic plasticity. The papers also discuss clinical guidelines and the evaluation of outcomes for various treatment approaches. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t11071 |
| Works | 422 |

## Topic papers all

Showing 15 of 422.

- [The PHQ-9](https://scholariq.org/papers/the-phq-9/)
- [The Patient Health Questionnaire-2](https://scholariq.org/papers/the-patient-health-questionnaire-2/)
- [Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia](https://scholariq.org/papers/effectiveness-of-antipsychotic-drugs-in-patients-with-chronic-schizophrenia/)
- [The PHQ-8 as a measure of current depression in the general population](https://scholariq.org/papers/the-phq-8-as-a-measure-of-current-depression-in-the-general-population/)
- [A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression](https://scholariq.org/papers/a-randomized-trial-of-an-n-methyl-d-aspartate-antagonist-in-treatment-resistant/)
- [An Ultra-Brief Screening Scale for Anxiety and Depression: The PHQ-4](https://scholariq.org/papers/an-ultra-brief-screening-scale-for-anxiety-and-depression-the-phq-4/)
- [Mediators and Moderators of Treatment Effects in Randomized Clinical Trials](https://scholariq.org/papers/mediators-and-moderators-of-treatment-effects-in-randomized-clinical-trials/)
- [Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis](https://scholariq.org/papers/comparative-efficacy-and-tolerability-of-15-antipsychotic-drugs-in-schizophrenia/)
- [Collaborative Care Management of Late-Life Depression in the Primary Care Setting](https://scholariq.org/papers/collaborative-care-management-of-late-life-depression-in-the-primary-care/)
- [Antidepressant Drug Effects and Depression Severity](https://scholariq.org/papers/antidepressant-drug-effects-and-depression-severity/)
- [Optimal cut-off score for diagnosing depression with the Patient Health Questionnaire (PHQ-9): a meta-analysis](https://scholariq.org/papers/optimal-cut-off-score-for-diagnosing-depression-with-the-patient-health/)
- [Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis](https://scholariq.org/papers/screening-for-anxiety-disorders-with-the-gad-7-and-gad-2-a-systematic-review-and/)
- [Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis](https://scholariq.org/papers/comparative-efficacy-and-acceptability-of-12-new-generation-antidepressants-a/)
- [Valvular Heart Disease Associated with Fenfluramine–Phentermine](https://scholariq.org/papers/valvular-heart-disease-associated-with-fenfluramine-phentermine/)
- [Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression.](https://scholariq.org/papers/randomized-trial-of-behavioral-activation-cognitive-therapy-and-antidepressant/)

## Topic primary papers

Showing 15 of 152.

- [A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression](https://scholariq.org/papers/a-randomized-trial-of-an-n-methyl-d-aspartate-antagonist-in-treatment-resistant/)
- [Antidepressant Drug Effects and Depression Severity](https://scholariq.org/papers/antidepressant-drug-effects-and-depression-severity/)
- [Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis](https://scholariq.org/papers/comparative-efficacy-and-acceptability-of-12-new-generation-antidepressants-a/)
- [Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression.](https://scholariq.org/papers/randomized-trial-of-behavioral-activation-cognitive-therapy-and-antidepressant/)
- [Cognitive Therapy vs Medications in the Treatment of Moderate to Severe Depression](https://scholariq.org/papers/cognitive-therapy-vs-medications-in-the-treatment-of-moderate-to-severe/)
- [Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review](https://scholariq.org/papers/relapse-prevention-with-antidepressant-drug-treatment-in-depressive-disorders-a/)
- [Comparative efficacy of cognitive therapy and pharmacotherapy in the treatment of depressed outpatients](https://scholariq.org/papers/comparative-efficacy-of-cognitive-therapy-and-pharmacotherapy-in-the-treatment/)
- [Major depressive disorder: new clinical, neurobiological, and treatment perspectives](https://scholariq.org/papers/major-depressive-disorder-new-clinical-neurobiological-and-treatment/)
- [Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study](https://scholariq.org/papers/efficacy-and-safety-of-flexibly-dosed-esketamine-nasal-spray-combined-with-a/)
- [Antidepressant use and risk of adverse outcomes in older people: population based cohort study](https://scholariq.org/papers/antidepressant-use-and-risk-of-adverse-outcomes-in-older-people-population-based/)
- [Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression](https://scholariq.org/papers/efficacy-of-esketamine-nasal-spray-plus-oral-antidepressant-treatment-for/)
- [Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines](https://scholariq.org/papers/evidence-based-guidelines-for-treating-depressive-disorders-with-antidepressants/)
- [A review on cognitive impairments in depressive and anxiety disorders with a focus on young adults](https://scholariq.org/papers/a-review-on-cognitive-impairments-in-depressive-and-anxiety-disorders-with-a/)
- [Prevention of Relapse Following Cognitive Therapy vs Medications in Moderate to Severe Depression](https://scholariq.org/papers/prevention-of-relapse-following-cognitive-therapy-vs-medications-in-moderate-to/)
- [Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression](https://scholariq.org/papers/efficacy-and-safety-of-intranasal-esketamine-adjunctive-to-oral-antidepressant/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.